Completed PHASE4 INTERVENTIONAL 2-arm NCT03466983

A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Sponsor: Pharmacosmos A/S

Conditions IBD

Interventions Ferric Carboxymaltose Iron Isomaltoside

Updated 8 times since 2018 Last updated: Feb 18, 2021 Started: May 23, 2018 Primary completion: May 25, 2020 Completion: May 25, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates IBD and is currently completed. Pharmacosmos A/S leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE4
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE4

▶ Show 3 earlier versions

Sep 2018 — Apr 2020 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Sep 2018 [monthly]

Not Yet Recruiting PHASE4
Apr 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharmacosmos A/S

Data source: Pharmacosmos A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Silkeborg, Denmark